A recent summit explored how technological advances could impact patient care.

Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.

The RUXCOVID clinical trial highlights the Novartis commitment to leverage our expertise and resources to support the global response to the COVID-19 pandemic.

The Co-Creating Impact Summit happening on December 9th, 2020, will gather experts inside and outside of Novartis to continue our work of improving our impact on the society and the planet.

Fourteen weeks. That’s how many weeks all new Novartis parents will get as minimum paid parental leave, regardless of gender, rolling out from July 1, 2019.

Blood diseases place a huge burden on individual patients, their families and on wider society. Yet advances in hematology treatment give so much cause for hope. It’s our responsibility to turn that hope into reality. Hear from five bold advocates who inspire us.

Novartis and other industry leaders call for action to address antimicrobial resistance, one of the world’s most serious public health challenges